{"id":10156,"date":"2020-12-02T22:03:03","date_gmt":"2020-12-02T13:03:03","guid":{"rendered":"http:\/\/cell.brc.riken.jp\/en\/?page_id=10156"},"modified":"2025-08-04T14:38:19","modified_gmt":"2025-08-04T05:38:19","slug":"diseaselist_4","status":"publish","type":"page","link":"http:\/\/cell.brc.riken.jp\/en\/hps\/patient_specific_ips\/diseaselist_4","title":{"rendered":"Immune diseases"},"content":{"rendered":"

\uff0a When you want to use some Disease-specific iPS cells, please e-mail to the following address.
\n\uff0a In relation to the information that are not described below, please e-mail to the following address.<\/p>\n

Contact us :\u00a0cellips.brc\"\"riken.jp<\/a><\/p>\n

Blue letter cells are available. You obtain the information by clicking the blue letter.
\n*iPS cells created using the Sendai virus vector are now available<\/a><\/p>\n

*Terms:
\nIn relation to all iPS cell lines, approval of institutional review board and\/or institutional ethical committee regarding the research using iPS cells is necessary.
\nIn relation to all iPS cell lines, commercial use is prohibited.
\nIn relation to the cell lines marked with \u25ce, (1) the recipient does not need to obtain an approval from the depositor, (2) there is no need of collaboration with the depositor, and (3) for-profit entities can also utilize.<\/p>\n

Update : 2020.11.27<\/p>\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n
Name of diseases<\/th>\nPatient No.<\/th>\n*Terms<\/th>\nApproval Form<\/th>\nHPS<\/th>\n<\/th>\n<\/th>\n<\/th>\n<\/th>\n<\/th>\n<\/th>\n<\/th>\n<\/th>\nReferences<\/th>\n<\/tr>\n
Immune diseases<\/span><\/strong><\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/tr>\n
1. Takayasu arteritis<\/span><\/strong><\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/tr>\n
Takayasu arteritis, unclassified<\/td>\n1<\/span><\/td>\n\u25ce<\/td>\nUnnecessary<\/td>\nHPS1192<\/td>\nHPS1193<\/td>\nHPS1194<\/td>\nHPS1195<\/td>\nHPS1196<\/td>\nHPS1197<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/tr>\n
Takayasu arteritis, mixed type<\/td>\n1<\/td>\n\u25ce<\/td>\nUnnecessary<\/td>\nHPS2072<\/td>\nHPS2073<\/td>\nHPS2074<\/td>\nHPS2075<\/td>\nHPS2076<\/td>\nHPS2077<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/tr>\n
2<\/td>\n\u25ce<\/td>\nUnnecessary<\/td>\nHPS2774<\/td>\nHPS2775<\/td>\nHPS2776<\/td>\nHPS2777<\/td>\nHPS2778<\/td>\nHPS2779<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/tr>\n
Takayasu arteritis, atypical coarctation of aorta<\/td>\n<\/a>1<\/span><\/td>\n\u25ce<\/td>\nUnnecessary<\/td>\nHPS2995<\/td>\nHPS2996<\/td>\nHPS2997<\/td>\nHPS2998<\/td>\nHPS2999<\/td>\nHPS3000<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/tr>\n
2. Giant cell arteritis (GCA)<\/span><\/strong><\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/tr>\n
Giant cell arteritis (GCA)<\/td>\n1<\/td>\n\u25ce<\/td>\nUnnecessary<\/td>\nHPS2244<\/td>\nHPS2245<\/td>\nHPS2246<\/td>\nHPS2247<\/td>\nHPS2248<\/td>\nHPS2249<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/tr>\n
2<\/td>\n\u25ce<\/td>\nUnnecessary<\/td>\nHPS3320<\/td>\nHPS3321<\/td>\nHPS3322<\/td>\nHPS3323<\/td>\nHPS3324<\/td>\nHPS3325<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/tr>\n
Giant cell arteritis (GCA), regional type<\/td>\n<\/a>1<\/span><\/td>\n\u25ce<\/td>\nUnnecessary<\/td>\nHPS1579<\/td>\nHPS1580<\/td>\nHPS1581<\/td>\nHPS1582<\/td>\nHPS1583<\/td>\nHPS1584<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/tr>\n
3. Polyarteritis nodosa (PAN)<\/span><\/strong><\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/tr>\n
Polyarteritis nodosa (PAN)<\/td>\n1<\/span><\/td>\n\u25ce<\/td>\nUnnecessary<\/td>\nHPS2256<\/td>\nHPS2257<\/td>\nHPS2258<\/td>\nHPS2259<\/td>\nHPS2260<\/td>\nHPS2261<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/tr>\n
Polyarteritis nodosa\u00a0(PAN), MPO-ANCA(+)<\/td>\n<\/a>1<\/span><\/td>\n\u25ce<\/td>\nUnnecessary<\/td>\nHPS1306<\/td>\nHPS1307<\/td>\nHPS1308<\/td>\nHPS1309<\/td>\nHPS1310<\/td>\nHPS1311<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/tr>\n
4. Microscopic polyangiitis \uff08MPA)<\/span><\/strong><\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/tr>\n
Microscopic polyangiitis \uff08MPA)<\/td>\n1<\/td>\n\u25ce<\/td>\nUnnecessary<\/td>\nHPS2144<\/td>\nHPS2145<\/td>\nHPS2146<\/td>\nHPS2147<\/td>\nHPS2148<\/td>\nHPS2149<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/tr>\n
<\/a>2<\/td>\n\u25ce<\/td>\nUnnecessary<\/td>\nHPS2325<\/td>\nHPS2326<\/td>\nHPS2327<\/td>\nHPS2328<\/td>\nHPS2329<\/td>\nHPS2330<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/tr>\n
5. Granulomatosis with polyangiitis (GPA)<\/span><\/strong><\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/tr>\n
Granulomatosis with polyangiitis (GPA)<\/td>\n1<\/td>\n\u25ce<\/td>\nUnnecessary<\/td>\nHPS1679<\/a><\/td>\nHPS1680<\/td>\nHPS1681<\/td>\nHPS1682<\/td>\nHPS1683<\/td>\nHPS1684<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/tr>\n
<\/a>2<\/td>\n\u25ce<\/td>\nUnnecessary<\/td>\nHPS2186<\/a><\/td>\nHPS2187<\/td>\nHPS2188<\/td>\nHPS2189<\/td>\nHPS2190<\/td>\nHPS2191<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/tr>\n
6. Eosinophilic granulomatosis with polyangiitis (EGPA)<\/a><\/span><\/strong><\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/tr>\n
Eosinophilic granulomatosis with polyangiitis (EGPA)<\/td>\n1<\/td>\n\u25ce<\/td>\nUnnecessary<\/td>\nHPS1472<\/a><\/td>\nHPS1473<\/td>\nHPS1474<\/td>\nHPS1475<\/td>\nHPS1476<\/td>\nHPS1477<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/tr>\n
2<\/td>\n\u25ce<\/td>\nUnnecessary<\/td>\nHPS2150<\/a><\/td>\nHPS2151<\/td>\nHPS2152<\/td>\nHPS2153<\/td>\nHPS2154<\/td>\nHPS2155<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/tr>\n
Allergic granulomatous angiitis<\/td>\n<\/a>1<\/span><\/td>\n\u25ce<\/td>\nUnnecessary<\/td>\nHPS1918<\/td>\nHPS1919<\/td>\nHPS1920<\/td>\nHPS1921<\/td>\nHPS1922<\/td>\nHPS1923<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/tr>\n
7. Malignant rheumatoid arthritis (MRA)<\/span><\/strong><\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/tr>\n
Malignant rheumatoid arthritis (MRA)<\/td>\n1<\/td>\n\u25ce<\/td>\nUnnecessary<\/td>\nHPS1691<\/td>\nHPS1692<\/td>\nHPS1693<\/td>\nHPS1694<\/td>\nHPS1695<\/td>\nHPS1696<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/tr>\n
<\/a>2<\/td>\n\u25ce<\/td>\nUnnecessary<\/td>\nHPS2365<\/td>\nHPS2366<\/td>\nHPS2367<\/td>\nHPS2368<\/td>\nHPS2369<\/td>\nHPS2370<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/tr>\n
8. Buerger\u2019s disease<\/span><\/strong><\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/tr>\n
Buerger’s disease<\/td>\n1<\/td>\n\u25ce<\/td>\nUnnecessary<\/td>\nHPS1379<\/td>\nHPS1380<\/td>\nHPS1381<\/td>\nHPS1382<\/td>\nHPS1383<\/td>\nHPS1384<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/tr>\n
<\/a>2<\/td>\n\u25ce<\/td>\nUnnecessary<\/td>\nHPS2102<\/td>\nHPS2103<\/td>\nHPS2104<\/td>\nHPS2105<\/td>\nHPS2106<\/td>\nHPS2107<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/tr>\n
9. Primary antiphospholipid syndrome, APS with venous and<\/span><\/strong><\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/tr>\n
Primary antiphospholipid syndrome, APS with venous and arterial events<\/td>\n1<\/span><\/td>\n\u25ce<\/td>\nUnnecessary<\/td>\nHPS2660<\/td>\nHPS2661<\/td>\nHPS2662<\/td>\nHPS2663<\/td>\nHPS2664<\/td>\nHPS2665<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/tr>\n
Primary antiphospholipid syndrome, complicated with pemphigoid<\/td>\n<\/a>1<\/span><\/td>\n\u25ce<\/td>\nUnnecessary<\/td>\nHPS3191<\/td>\nHPS3192<\/td>\nHPS3193<\/td>\nHPS3194<\/td>\nHPS3195<\/td>\nHPS3196<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/tr>\n
10. Systemic lupus erythematosus (SLE)<\/span><\/strong><\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/tr>\n
Systemic lupus erythematosus (SLE)<\/td>\n1<\/td>\n<\/td>\n<\/td>\nHPS1752*<\/td>\nHPS1753*<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/tr>\n
2<\/td>\n<\/td>\n<\/td>\nHPS1754*<\/td>\nHPS1755*<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/tr>\n
<\/a>3<\/td>\n\u25ce<\/td>\nUnnecessary<\/td>\nHPS2684<\/td>\nHPS2685<\/td>\nHPS2686<\/td>\nHPS2687<\/td>\nHPS2688<\/td>\nHPS2689<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/tr>\n
<\/a>4<\/td>\n<\/td>\nUnnecessary<\/td>\nHPS3956* <\/td>\nHPS3957* <\/td>\nHPS3958* <\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/tr>\n
<\/a>5<\/td>\n<\/td>\nUnnecessary<\/td>\nHPS3968* \"NEW\"<\/td>\nHPS3969* \"NEW\"<\/td>\nHPS3970* \"NEW\"<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/tr>\n
11. Dermatomyositis (DM)\/Polymyositis (PM)<\/span><\/strong><\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/tr>\n
Dermatomyositis (DM)<\/td>\n1<\/td>\n<\/td>\n<\/td>\nHPS0174*<\/a><\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/tr>\n
2<\/td>\n\u25ce<\/td>\nUnnecessary<\/td>\nHPS2424<\/td>\nHPS2425<\/td>\nHPS2426<\/td>\nHPS2427<\/td>\nHPS2428<\/td>\nHPS2429<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/tr>\n
Polymyositis (PM)<\/td>\n1<\/td>\n<\/td>\n<\/td>\nHPS1788*<\/td>\nHPS1789*<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/tr>\n
2<\/td>\n<\/td>\n<\/td>\nHPS1790*<\/td>\nHPS1791*<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/tr>\n
3<\/td>\n<\/td>\n<\/td>\nHPS1841*<\/td>\nHPS1842*<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/tr>\n
<\/a>4<\/td>\n<\/td>\n<\/td>\nHPS3658*<\/td>\nHPS3659*<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/tr>\n
<\/a>5<\/td>\n<\/td>\nUnnecessary<\/td>\nHPS3965* \"NEW\"<\/td>\nHPS3966* \"NEW\"<\/td>\nHPS3967* \"NEW\"<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/tr>\n
12. Mixed Connective-Tissue Disease (MCTD)<\/span><\/strong><\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/tr>\n
Mixed Connective-Tissue Disease (MCTD), anti U1-RNP antibody(+)<\/td>\n1<\/td>\n\u25ce<\/td>\nUnnecessary<\/td>\nHPS1288<\/td>\nHPS1289<\/td>\nHPS1290<\/td>\nHPS1291<\/td>\nHPS1292<\/td>\nHPS1293<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/tr>\n
<\/a>2<\/td>\n\u25ce<\/td>\nUnnecessary<\/td>\nHPS2654<\/td>\nHPS2655<\/td>\nHPS2656<\/td>\nHPS2657<\/td>\nHPS2658<\/td>\nHPS2659<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/tr>\n
13. Sj\u00f6gren\u2019s syndrome<\/span><\/strong><\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/tr>\n
Sj\u00f6gren’s syndrome<\/td>\n1<\/td>\n\u25ce<\/td>\nUnnecessary<\/td>\nHPS0437<\/a><\/td>\nHPS0438<\/td>\nHPS0439<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\nPMID: 23193063<\/a>
\n24399248<\/a><\/td>\n<\/tr>\n
HPS0706<\/td>\nHPS0707<\/td>\nHPS0708<\/td>\nHPS0709<\/td>\nHPS0710<\/td>\nHPS0711<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/tr>\n
<\/a>2<\/td>\n<\/td>\n<\/td>\nHPS1777*<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/tr>\n
14. Adult-onset Still\u2019s disease (AOSD)<\/span><\/strong><\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/tr>\n
Adult-onset Still’s disease (AOSD)<\/td>\n1<\/td>\n\u25ce<\/td>\nUnnecessary<\/td>\nHPS2562<\/td>\nHPS2563<\/td>\nHPS2564<\/td>\nHPS2565<\/td>\nHPS2566<\/td>\nHPS2567<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/tr>\n
<\/a>2<\/td>\n\u25ce<\/td>\nUnnecessary<\/td>\nHPS2708<\/td>\nHPS2709<\/td>\nHPS2710<\/td>\nHPS2711<\/td>\nHPS2712<\/td>\nHPS2713<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/tr>\n
15. Relapsing polychondritis (RP)<\/span><\/strong><\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/tr>\n
Relapsing polychondritis (RP)<\/td>\n<\/a>1<\/td>\n\u25ce<\/td>\nUnnecessary<\/td>\nHPS1988<\/a><\/td>\nHPS1989<\/td>\nHPS1990<\/td>\nHPS1991<\/td>\nHPS1992<\/td>\nHPS1993<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/tr>\n
16. Beh\u00e7et\u2019s disease<\/span><\/strong><\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/tr>\n
Beh\u00e7et\u2019s disease,\u00a0complete type<\/td>\n1<\/td>\n\u25ce<\/td>\nUnnecessary<\/td>\nHPS1294<\/td>\nHPS1295<\/td>\nHPS1296<\/td>\nHPS1297<\/td>\nHPS1298<\/td>\nHPS1299<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/tr>\n
Beh\u00e7et\u2019s disease, neuro-Beh\u00e7et\u2019s disease\/ HLA-B51<\/td>\n1<\/td>\n\u25ce<\/td>\nUnnecessary<\/td>\nHPS2060<\/td>\nHPS2061<\/td>\nHPS2062<\/td>\nHPS2063<\/td>\nHPS2064<\/td>\nHPS2065<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/tr>\n
<\/a>2<\/td>\n\u25ce<\/td>\nUnnecessary<\/td>\nHPS2466<\/td>\nHPS2467<\/td>\nHPS2468<\/td>\nHPS2469<\/td>\nHPS2470<\/td>\nHPS2471<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/tr>\n
17. Chronic infantile neurological cutaneous and articular syndrome (CINCA syndrome<\/span><\/strong><\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/tr>\n
Chronic infantile neurological cutaneous and articular syndrome (CINCA syndrome), somatic mosaicism<\/td>\n1<\/td>\n<\/td>\n<\/td>\nHPS0117<\/a><\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\nPMID: 22723549<\/a><\/td>\n<\/tr>\n
<\/a>2<\/td>\n<\/td>\n<\/td>\nHPS0119<\/a><\/td>\nHPS0120<\/a><\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\nPMID: 22723549<\/a><\/td>\n<\/tr>\n
18. TNF receptor-associated periodic syndrome <\/span><\/strong><\/a><\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/tr>\n
TNF receptor-associated periodic syndrome<\/td>\n<\/a>1<\/td>\n\u25ce<\/td>\nUnnecessary<\/td>\nHPS3203<\/td>\nHPS3204<\/td>\nHPS3205<\/td>\nHPS3506<\/td>\nHPS3207<\/td>\nHPS3208<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/tr>\n
19. Familial Mediterranean fever,<\/span><\/strong><\/a><\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/tr>\n
Familial Mediterranean fever, typical FMF<\/td>\n1<\/td>\n\u25ce<\/td>\nUnnecessary<\/td>\nHPS2924<\/td>\nHPS2925<\/td>\nHPS2926<\/td>\nHPS2927<\/td>\nHPS2928<\/td>\nHPS2929<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/tr>\n
20. Nakajo-Nishimura Syndrome<\/span><\/strong><\/a><\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/tr>\n
Nakajo-Nishimura Syndrome<\/td>\n1<\/td>\n<\/td>\n<\/td>\nHPS0517<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/tr>\n
2<\/td>\n<\/td>\n<\/td>\nHPS0518<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/tr>\n
21. Pyogenic sterile arthritis, pyoderma gangrenosum and acne syndrome <\/span><\/strong><\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/tr>\n
Pyogenic sterile arthritis, pyoderma gangrenosum and acne syndrome<\/td>\n1<\/td>\n\u25ce<\/td>\nUnnecessary<\/td>\nHPS2604<\/td>\nHPS2605<\/td>\nHPS2606<\/td>\nHPS2607<\/td>\nHPS2608<\/td>\nHPS2609<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/tr>\n
22. IgG4-related disease<\/span><\/strong><\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/tr>\n
IgG4-related disease, IgG4-related thyroid disease<\/td>\n1<\/td>\n\u25ce<\/td>\nUnnecessary<\/td>\nHPS2672<\/td>\nHPS2673<\/td>\nHPS2674<\/td>\nHPS2675<\/td>\nHPS2676<\/td>\nHPS2677<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/tr>\n
23. Eosinophilic sinusitis<\/span><\/strong><\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/tr>\n
Eosinophilic sinusitis<\/td>\n1<\/td>\n\u25ce<\/td>\nUnnecessary<\/td>\nHPS2918<\/td>\nHPS2919<\/td>\nHPS2920<\/td>\nHPS2921<\/td>\nHPS2922<\/td>\nHPS2923<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n","protected":false},"excerpt":{"rendered":"

\uff0a When you want to use some Disease-specific iPS cells, please e-mail to the following address. \uff0a In relation to the information that are not described below, please e-mail to the following address. Contact us :\u00a0cellips.brcriken.jp Blue letter cells are available. You obtain the information by clicking the blue letter. *iPS cells created using the Sendai virus vector are now available *Terms: In relation to all iPS cell lines, approval of institutional review board and\/or institutional ethical committee regarding the research using iPS cells is necessary. In relation to all iPS cell lines, commercial use is prohibited. In relation to the cell lines marked with \u25ce, (1) the recipient does not need to obtain an approval from the depositor, (2) there is no need of collaboration with the depositor, and (3) for-profit entities can also utilize. Update : 2020.11.27 Name of diseases Patient No. *Terms Approval Form HPS References Immune diseases 1. Takayasu arteritis Takayasu arteritis, unclassified 1 \u25ce Unnecessary HPS1192 HPS1193 HPS1194 HPS1195 HPS1196 HPS1197 Takayasu arteritis, mixed type 1 \u25ce Unnecessary HPS2072 HPS2073 HPS2074 HPS2075 HPS2076 HPS2077 2 \u25ce Unnecessary HPS2774 HPS2775 HPS2776 HPS2777 HPS2778 HPS2779 Takayasu arteritis, atypical coarctation of aorta 1 \u25ce Unnecessary HPS2995 HPS2996 HPS2997 […]<\/p>\n","protected":false},"author":15,"featured_media":0,"parent":10124,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"_seopress_titles_title":"","_seopress_titles_desc":"","_seopress_robots_index":"","_seopress_robots_follow":"","_seopress_robots_imageindex":"","_seopress_robots_snippet":"","_seopress_robots_primary_cat":"","_seopress_robots_breadcrumbs":"","_seopress_robots_freeze_modified_date":"","_seopress_robots_custom_modified_date":"","_seopress_robots_canonical":"","_seopress_social_fb_title":"","_seopress_social_fb_desc":"","_seopress_social_fb_img":"","_seopress_social_fb_img_attachment_id":0,"_seopress_social_fb_img_width":0,"_seopress_social_fb_img_height":0,"_seopress_social_twitter_title":"","_seopress_social_twitter_desc":"","_seopress_social_twitter_img":"","_seopress_social_twitter_img_attachment_id":0,"_seopress_social_twitter_img_width":0,"_seopress_social_twitter_img_height":0,"_seopress_redirections_value":"","_seopress_redirections_enabled":"","_seopress_redirections_enabled_regex":"","_seopress_redirections_logged_status":"both","_seopress_redirections_param":"","_seopress_redirections_type":301,"_seopress_analysis_target_kw":"","footnotes":"","_wp_rev_ctl_limit":""},"class_list":["post-10156","page","type-page","status-publish","hentry"],"_links":{"self":[{"href":"http:\/\/cell.brc.riken.jp\/en\/wp-json\/wp\/v2\/pages\/10156","targetHints":{"allow":["GET"]}}],"collection":[{"href":"http:\/\/cell.brc.riken.jp\/en\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"http:\/\/cell.brc.riken.jp\/en\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"http:\/\/cell.brc.riken.jp\/en\/wp-json\/wp\/v2\/users\/15"}],"replies":[{"embeddable":true,"href":"http:\/\/cell.brc.riken.jp\/en\/wp-json\/wp\/v2\/comments?post=10156"}],"version-history":[{"count":3,"href":"http:\/\/cell.brc.riken.jp\/en\/wp-json\/wp\/v2\/pages\/10156\/revisions"}],"predecessor-version":[{"id":10804,"href":"http:\/\/cell.brc.riken.jp\/en\/wp-json\/wp\/v2\/pages\/10156\/revisions\/10804"}],"up":[{"embeddable":true,"href":"http:\/\/cell.brc.riken.jp\/en\/wp-json\/wp\/v2\/pages\/10124"}],"wp:attachment":[{"href":"http:\/\/cell.brc.riken.jp\/en\/wp-json\/wp\/v2\/media?parent=10156"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}